Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of BMS-955176 Formulations in Healthy Subjects
NCT02095886Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Mar 2014
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BMS-955176 in human immunodeficiency virus type 1 infection (HIV-1) (8 cohorts), sponsored by ViiV Healthcare. Primary endpoints: Maximum observed plasma concentration, Area under the plasma concentration-time curve from time zero extrapolated to infinite time and 1 more. Started Mar 2014; status: completed.
02
Drugs
BMS-955176
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02095886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02095886.